Similar success rates with bivalirudin and unfractionated heparin in bare-metal stent implantation

CardioVascular and Interventional Radiology

Volumn 30, Issue 5, 2007, Pages 906-911

  Hallak, Omar ^a   Shams, S Ali ^b   Broce, Mike ^a   Lavigne, P Scott ^a   Lucas, B Daniel ^a   Elhabyan, Abdul Karim ^a   Reyes, Bernardo J ^a,c  

^a CAMC Health System   (United States)

^b CHARLESTON AREA MEDICAL CENTER   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Anticoagulation; Bivalirudin; Heparin; Interventional Radiology; Peripheral Interventions

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG;

AGED; AMPUTATION; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMORAL ARTERY; HEART INFARCTION; HUMAN; ILIAC ARTERY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SAFETY; PRIORITY JOURNAL; RENAL ARTERY; RETROSPECTIVE STUDY; REVASCULARIZATION; STENT;

AGED; AMPUTATION; ANGIOPLASTY, BALLOON; ANTICOAGULANTS; ATHEROSCLEROSIS; FEMALE; FEMORAL ARTERY; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; ILIAC ARTERY; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PROSTHESIS DESIGN; RECOMBINANT PROTEINS; RENAL ARTERY; RESEARCH DESIGN; RETROSPECTIVE STUDIES; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 34848887671     PISSN: 01741551     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00270-007-9038-1     Document Type: Article

References (38)

1. Ouriel K (2001) Peripheral arterial disease. Lancet 358:1257-1264
2. Shammas NW, Dippel EJ (2005) Evidence-based management of peripheral vascular disease [review]. Curr Atheroscler Rep 7:358-363
3. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE (1998) Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114(5 Suppl):489S-510S
4. Hirsh J (1991) Heparin. N Engl J Med 324:1565-1574
5. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ (2001) Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142:952-959
6. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA (2000) Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 11:149-161
7. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators (2004) Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292:696-703
8. Henry TD (2002) Overcoming heparin limitations in high-risk percutaneous coronary intervention: The alternative strategy-replacing heparin with bivalirudin. J Invas Cardiol 14 (Suppl B):19-39
9. Chu WW, Kuchulakanti PK, Wang B, Torguson R, Clavijo C, Pichard AD, Suddath WO, Satler LF, Kent KM, Waksman R (2006) Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Cardiovasc Revasc Med 7:132-135
10. Yehudai L, Feit F (2006) Debate of adjunctive pharmacology for percutaneous coronary intervention: Thrombin inhibitors and clopidogrel are enough. J Interv Cardiol 19:464-469
11. Allie DE, Lirtzman MD, Wyatt CH, Keller VA, Khan MH, Khan MA, Fail PS, Hebert CJ, Ellis SD, Mitran E, Chaisson G, Stagg S Jr, Allie AA, Walker CM (2003) Bivalirudin as a foundation anticoagulant in peripheral vascular disease: A safe and feasible alternative for renal and iliac interventions. J Invas Cardiol 15:334-342
12. Rundback J, Sacks D, Kent C, Cooper C, Jones D, Morphy T, Rosenfield K, White C, Bettmann M, Cortell S, Pushett J, Clair D, Cole P for the American Councils on Cardiovascular Radiology, High Blood Pressure Research, Kidney in Cardiovascular Disease, Cardio-Thoracic and Vascular Surgery, and Clinical Cardiology, and the Society for Interventional Radiology FDA Device Forum Committee (2002) Guidelines for the reporting of renal artery revascularization in clinical trials. Circulation 106:1572-1585
13. Technology Assessment Committee (1997) Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol 8:137-149
14. Rajan DK, Patel NH, Valji K, Cardella JF, Bakal C, et al (2005) Quality improvement guidelines for percutaneous management of acute limb ischemia. J Vasc Interv Radiol 16:585-595
15. Bovill EG, Terrin ML, Stump DC, et al (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115:256-265
16. Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE (2000) Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 139:696-703
17. Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, Kusumoto S, Blystone SD, Suda Y (2001) Heparin modulates integrin function in human platelets. J Vasc Surg 33:587-594
18. Xiao Z, Theroux P (1998) Platelet activation with UFH at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97:251-256
19. Barzu T, Molho P, Tobelem G, Petitou M, Caen J (1985) Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 845:196-203
20. Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67:639-643
21. Kelton JG, Warkentin TE (1998) Heparin-induced thrombocytopenia: Diagnosis, natural history and treatment options. Postgrad Med 103:169-178
22. Moen MD, Keating GM, Wellington K (2005) Bivalirudin: A review of its use in patients undergoing percutaneous coronary intervention. Drugs 65:1869-1891
23. Allie DE, Hebert CJ, Lirtzman MD, Wyatt CH, Keller VA, Khan MH, Khan MA, Fail PS, Vivekananthan K, Allie SE, Mitran EV, Chaisson G, Stagg SJ 3rd, Allie AA, McElderry MW, Barker EA, Walker CM (2005) A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: Treating critical limb ischemia like acute coronary syndrome. J Invas Cardiol 17:427-432
24. Ebrahimi R, Lincoff AM, Bittl JA, Chew D, Wolski K, Wadhan N, Toggart EJ, Topol EJ (2005) Bivalirudin vs heparin in percutaneous coronary intervention: A pooled analysis. J Cardiovasc Pharmacol Ther 10:209-216
25. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ; REPLACE-1 Investigators (2004) Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93:1092-1096
26. Hillegass WB (2005) PCI with bivalirudin and provisional GP IIb/IIIa inhibition is more cost-effective than heparin plus routine GP IIb/IIIa inhibition. Commentary. Evid Based Cardiovasc Med 9:68-71
27. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ; REPLACE-2 Investigators (2005) Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95:581-585
28. Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, Lincoff AM (2005) Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: An analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 45:1932-1938
29. Yegin A, Corrigan VE, Lembo NJ, Knapp WS, Bernstein C, Chronos NA, Knopf WD (2002) Bivalirudin anticoagulation is safe and feasible in elective percutaneous intervention for peripheral arterial disease. Atlanta, GA: American Cardiovascular Research Institute (ACRI), Atlanta Cardiology Group
30. Katzen BT, Ardid MI, MacLean AA, Kovacs MF, Zemel G, Benenati JF, Powell A, Samuels S (2005) Bivalirudin as an anticoagulation agent: Safety and efficacy in peripheral interventions. J Vasc Interv Radiol 16:1183-1187; quiz 1187
31. Shammas NW, Allie D, Hall P, Young J, Laird J, Safian R, Virmani A; APPROVE Investigators (2005) Predictors of in-hospital and 30-day complications of peripheral vascular interventions using bivalirudin as the primary anticoagulant: Results from the APPROVE Registry. J Invas Cardiol 17:356-359
32. Shammas NW, Lemke JH, Dippel EJ, McKinney DE, Takes VS, Youngblut M, Harris M, Harb C, Kapalis MJ, Holden J (2003) In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invas Cardiol 15:242-246
33. Ormiston JA, Shaw BL, Panther MJ, Ruygrok PN, Davlin GP, Stewart RAH, Webster MWI (2002) Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: A feasibility study with implications for day-stay procedures. Catheter Cardiovasc Interv 55:289-293
34. Chacko M, Lincoff MA, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen M, Chew DP, Cho L, Topol EJ (2006) Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 151:1032.e1-1032.e7
35. Koster A, Spiess B, Jurmann M, Dyke CM, Sedira NG, Aronson S, Lincoff M (2006) Bivalirudin provides rapid, effective and reliable anticoagulation during off-pump coronary revascularization: Results of the "EVOLUTION OFF" trial [cardiovascular anesthesia]. Anesth Analg 103:540-544
36. Sorin BJ, Moliterno DJ, Lincoff MA, Steinhubl SR, Wolski KE, Topol EJ (2004) Relationship between activated clotting time and ischemic or hemorrhagic complications. Circulation 100:994-998
37. Package Insert Angiomax TMC PN 1002-5 (11/12/03)
38. Patel N, Sacks D, Patel RI, Moresco KP, Ouriel K, Gray R, Ambrosius WT, Lewis CA, the members of the Society of Interventional Radiology Technology Assessment Committee (2003) SIR reporting standards for the treatment of acute limb ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol 14:S453-S4654